Experience When it Matters Most

EXECUTIVE SUMMARY

The Opportunity. More than 55 million American women are in perimenopause or menopause at any given time, with 1.3 million new cases each year. Virtually all of them already have an OB-GYN. Yet 95% are never offered treatment by their physician (Boston Consulting Group (BCG) 2025), only 29% even seek care (Mayo Clinic, 2025), and 35% require four or more visits before their symptoms are correctly linked to hormonal changes. This is not a demand problem. Women are actively seeking care. The gap reflects systemic constraints in training pipelines, reimbursement structures, and visit economics that have left even motivated OB-GYNs without the time, tools, or curriculum to address menopause at scale.

The Stakes. The economic footprint is real: $26.6 billion in annual U.S. costs (Mayo Clinic, 2023), a 10% post-menopause earnings penalty for affected women (Stanford, 2025), and a $40 billion clinical market validated by BCG, PwC, and the Milken Institute. PwC projects women’s health will exceed $600 billion by 2030. Between 2020 and 2025, nearly $60 billion in private capital flowed into women’s health, and menopause is now the fastest-growing subcategory, growing at 13% annually. Every dollar of that capital flows through a gap OB-GYN practices have, highlighting the opportunity for Women’s care practices.

Why OB-GYNs Didn’t Take Advantage of Opportunity. Five structural forces explain the gap: (1) Training gaps at the residency level only 31% of OB-GYN residencies offer any menopause curriculum and just 7% of residents feel adequately prepared (ACGME does not require it); (2) Post-WHI fear, one in three residents would not prescribe HRT to an eligible symptomatic patient, despite a now-favorable risk-benefit profile for women under 60 within 10 years of onset; (3) Practice economics a 45–75 minute counseling visit cannot compete with procedural RVUs in a 12–17 minute visit schedule; (4) Workforce shortage national OB-GYN demand is already underserved, with a projected shortfall of ~7,800 physicians by 2037 and 10.1 million women in OB-GYN deserts; (5) Cultural framing — menopause has been treated as a lifecycle inevitability rather than a clinical condition, so patients learn not to ask and providers learn not to probe.

Why Now. Six forces have converged: rehabilitated HRT evidence, the first new non-hormonal drug class in 20 years (Astellas’ Veozah, FDA-approved May 2023), mainstream cultural destigmatization, a $50M federal CARE research initiative, employer benefit adoption tripling from 4% to ~12% (Mercer, 2022–2024), and post-COVID telehealth infrastructure operating at scale (Midi Health serves 20,000 women per week).

Who Is Filling the Vacuum.  Six categories of non-OB-GYN players are capturing the unmet demand: PE-backed OB-GYN platforms (Unified, Together, Axia, and Advantia), digital health and telehealth startups (Midi, the first menopause unicorn at $1B+ valuation in Feb 2026; Hims & Hers; Evernow; Maven), consumer CPG brands (Bonafide acquired by Pharmavite for $425M; now on Target shelves), employer benefit platforms (Maven, Progyny, and Carrot, distributing care to 30M+ employees), and pharmaceutical companies. A countermovement of MSCP-certified OB-GYNs is emerging at Mayo, NYU Langone, UCLA, Northwestern, Hoag, AHN, and independent practices like Elite Gynecology & Wellness and The MP Collective, but nationally, there are only 4,100 MSCPs, meaning one menopause specialist serves 13,400 affected women.

The Path Forward. OB-GYNs hold three advantages no competitor can replicate: existing patient relationships (the affected women are already in the waiting room), a full clinical scope (only OB-GYNs can deliver HRT plus surgical, oncologic, and cardiovascular co-management), and insurance credibility. Practices that act now, pursuing MSCP certification, building dedicated appointment architecture, integrating ancillary revenue (HRT monitoring, DXA, labs), adding a telehealth layer, and joining employer benefit networks report menopause becoming a top 3 revenue line within 18–24 months. Those who wait will find the market owned by others. The $40 billion opportunity exists precisely because the specialty best positioned to serve it has been constrained from doing so at scale. Those constraints are now lifting, and the practices that move first will define the next era of menopause care.

THE MENOPAUSE CARE GAP:
A STRATEGIC OPPORTUNITY
FOROB-GYN PRACTICES

TABLE OF CONTENTS

1. Capital Flowing into Women’s Health & Menopause
2. The Need and Why the Moment Is Now
3. Why OB-GYNs Aren’t Capturing This Market
4. OB-GYNs Who Are Beginning to Lead
5. Independent OB-GYN Practices: The Models to Follow
6. Who Is Filling the OB-GYN Gap
7. The Path Forward for OB-GYN Practices
8. Appendix: Significant Menopause & Perimenopause Transactions (2023–2026)

1. Capital Flowing into Women’s Health & Menopause

The menopause care market is a rare convergence of a massive, underserved population (55M women), proven demand (women actively seeking care and being turned away), multiple viable business models, strong PE/VC returns, and cultural tailwinds accelerating adoption. PwC estimates women’s health will be $600B+ by 2030. Capital is not leading this market it is following a demand signal that OB-GYN practices created by not serving it

The financial commitment to the menopause market has reached an institutional scale. Between 2020 and 2025, nearly $60 billion of private capital flowed into core women’s health, and menopause is the fastest-growing investment subcategory at 13% annual growth (PwC, April 2026).

2. The Need and Why the Moment Is Now

Perimenopause typically begins in a woman’s early-to-mid 40s and can last 7 to 14 years before and after the final menstrual period. During this transition, women may experience more than 30 documented symptoms, including vasomotor symptoms (hot flashes, night sweats), sleep disruption, cognitive changes, mood dysregulation, genitourinary syndrome of menopause (GSM), accelerated bone density loss, cardiovascular risk escalation, and sexual dysfunction. These are not inconveniences. They are clinically significant, treatable conditions with documented long-term health consequences if left unaddressed.

The Confluence of Forces:

• Post-WHI Rehabilitation of Hormone Therapy: Recent analyses have improved the safety profile of HRT for women under 60 who start treatment within 10 years of menopause onset. Decades of pent-up demand are now being released.
• New FDA-Approved Non-Hormonal Option: Veozah (fezolinetant, Astellas) FDA approved May 2023. First new non-hormonal drug class for menopause in 20 years. Opens care for women who cannot use estrogen.
• Cultural Destigmatization: Oprah Winfrey, Naomi Watts, Drew Barrymore, and Halle Berry have driven menopause into mainstream cultural conversation. Destigmatization is the commercial prerequisite for market expansion. It has arrived.
• $50M CARE Research Initiative: The largest-ever investment in women’s brain health and menopause launched in 2025. NIH is directed by Congress to close the gender research gap. Federal tailwinds are accelerating investment timelines.
• Workforce Economics Forcing Employer Action: Stanford’s 10% earnings penalty study and Mayo Clinic’s $26.6B cost quantification gave employers the ROI data. Menopause benefit adoption tripled among large employers from 4% (2022) to ~12% (2024) (Mercer).
• Digital Infrastructure at Scale: Post-COVID telehealth normalization created the delivery infrastructure. Midi Health serves 20,000 women per week. Hims & Hers has 500,000+ subscribers. These scale levels were impossible in 2019.

3. Why OB-GYNs Aren’t Capturing This Market

The paradox is this: OB-GYNs are the providers best positioned by clinical training, patient relationships, and scope of practice to lead menopause care. The affected women are already in their waiting rooms. Yet women leave OB-GYN offices without diagnoses, without treatment plans, and without answers. Five structural forces explain why.

Lack of Training: Residency programs stopped teaching menopause medicine after the NIH’s 2002 Women’s Health Initiative (WHI) study, which reported increased risks of breast cancer and cardiovascular events with combined estrogen-progestin HRT, leading to a dramatic drop in hormone therapy prescribing and the near-abandonment of menopause training in OB-GYN residency programs.  Two decades later, the curriculum has not been restored at a meaningful scale.

 The OB-GYN Menopause Training Crisis — Residency Data

Contradictory Evidence: Even OB-GYNs with some menopause exposure carry the institutional scar of the 2002 WHI study, which generated massive publicity suggesting HRT caused breast cancer and heart attacks. The nuance that newer formulations in women under 60, initiated within 10 years of menopause onset, have a strongly favourable risk-benefit profile was never effectively communicated back to the medical community. In 2023, one-third of OB-GYN residents said they would NOT prescribe hormone therapy to a symptomatic, eligible patient. Women arrive asking for help and are turned away by physicians trained to fear the most effective treatment available. This physician-level avoidance is a primary reason telehealth startups (whose entire clinical model centres on HRT expertise) have been so successful.

Practice Model: Practices are financially engineered around high-revenue procedural service deliveries, C-sections, and laparoscopies. Menopause management is a 45-75 minute cognitive, counselling-intensive visit that codes as a standard E/M. A busy practice with a full obstetric panel faces direct revenue cannibalization when dedicating slots to menopause management.

• RVU Mismatch: Menopause counseling cannot compete with procedure-heavy revenue per hour under current reimbursement structures
• Claim Denial Rates: Women’s health claims face denial rates as high as 28% vs. 19% average additional friction for complex menopause visits
• No Defined Billing Pathway: Unlike some specialties, menopause has no standalone CPT code structure that incentivizes comprehensive visit architecture

Workforce Shortage: No Capacity to Expand

The Stigma and Normalization Gap: Menopause has been framed as a lifecycle inevitability to endure rather than a clinical condition to be treated. The annual well-woman visit is designed for screening and prevention — not chronic condition management. When a woman brings up hot flashes in a 15-minute well-woman visit, the provider has no protocol, no time, and often no training. Women learn not to ask. Providers learn not to probe.

4. OB-GYNs Who Are Beginning to Lead

A meaningful countermovement is underway. A growing cohort of OB-GYNs in academic medical centres, independent practices, and PE-backed platforms has identified menopause medicine as a clinical and business imperative and is building dedicated programs. These early movers are the template for what the broader speciality must do.

The MSCP Certification Movement: The MSCP credential — offered through The Menopause Society since 2002 — has become the primary signal of clinical expertise in menopause. MSCP growth is the most meaningful organized response to the OB-GYN training gap.

Dedicated Menopause Programs Launching Nationally:

5. Independent OB-GYN Practices: The Models to Follow

• Elite Gynecology & Wellness (FL): Entire team holds MSCP credentials; exclusively gynecology (no obstetrics); MSCP certification is the central brand differentiator practice built around menopause as a primary service line, not an afterthought
• Valley Medical Group (NJ): Four MSCP physicians on staff; integrated specialist network for cardiology, oncology, endocrinology, sleep, and metabolism; demonstrates the multi-specialty coordination model
• The MP Collective (Bryn Mawr, PA): OB-GYN-founded membership-based concierge menopause practice (2025); 90-minute personalized visits; complete medical history intake; bone density + HRT + lifestyle integration in a single practice model
• Ms. Medicine (Nationwide): MSCP-staffed telehealth practice focused exclusively on menopause medicine; demonstrates OB-GYN-credentialed providers competing directly with digital health startups on their own (virtual) turf

The early mover advantage: OB-GYN practices that earn MSCP certification, create dedicated appointment structures, and build ancillary revenue streams (HRT monitoring, labs, bone density, and supplements) report that menopause services become a top-3 revenue generator within 18-24 months. Patient panels, referral networks, and brand equity built now will be very difficult for later entrants to displace.

6. Who Is Filling the OB-GYN Gap

In the absence of adequate OB-GYN menopause care, six categories of players have built organizations, products, and services to capture the unmet demand. Each brings distinct competitive advantages and vulnerabilities.

PE-Backed OB-GYN Platforms:

Digital Health & Telehealth Startups:

• Midi Health ($250M+ raised through Series D, Feb 2026; valued at $1B+): 20,000 women/week; 500 clinicians; accepted by major PPO insurance in 50 states; Memorial Hermann + Lifepoint health system partnerships; Oura Ring data integration. The B2B2C health system partnership model is a critical strategic development. Midi becomes the new specialist layer for health systems that lack internal expertise.
• Hims & Hers (NYSE: HIMS): Menopause specialty launched Oct 2025, targeting $1B Hers revenue by 2026; 500K+ existing subscribers; affordable HRT access (estradiol, progesterone); cash-pay DTC targeting women never in the clinical system.
• Evernow ($28.5M): Pioneer of personalized menopause telehealth; clinician-matching model; individualized HRT plans.
• Maven Clinic ($500M+ funding): Women’s lifecycle benefit for 23M+ employees; menopause included; pivoting to DTC in 2026.
• Upliv (Northwell-backed): Hospital-system-incubated virtual menopause company (Nov 2024) — the health system’s own answer to telehealth competitors.

Consumer & CPG Brands: Pharmavite’s $425M acquisition of Bonafide Health (2023) validated the non-prescription menopause consumer market at an institutional scale. The September 2025 target launch placed Bonafide on mainstream retail shelves for the first time — completing the transition from speciality to mainstream consumer health. Key players: Bonafide (Pharmavite, $425M), Health & Her (6,000+ CVS stores), Kindra, Stripes (Naomi Watts), Womaness (Unilever Ventures).

Employer Benefit Platforms: Employer adoption of menopause benefits tripled among large employers from 4% (2022) to ~12% (2024) (Mercer). Maven Clinic (23M employees), Progyny (7.2M employees), and Carrot Fertility (4M+ employees) are competing for employer contracts – distributing menopause care through the HR benefits channel at enterprise scale.

Pharmaceutical Companies: Astellas’ Veozah (fezolinetant, FDA approved May 2023) — the first non-hormonal NK3 receptor antagonist for hot flashes — represents the most significant pharmaceutical menopause innovation in 20 years. At $550/month, it opens care for the estimated 15-20 million women who cannot safely use estrogen. (Note: In December 2024, the FDA added a Boxed Warning for rare but serious hepatotoxicity; prescribers must evaluate hepatic function before and during treatment.) Established HRT makers (AbbVie, Bayer, Pfizer/Wyeth) defend existing formulary positions as newer bioidentical generics gain share.

7. The Path Forward for OB-GYN Practices

Every barrier described in this white paper is addressable. The practices that move now will build patient panels, referral networks, and ancillary revenue that compound over time. Those that wait will find the market occupied by well-capitalized outsiders who built their models specifically because OB-GYNs did not act.

The Structural Advantages OB-GYNs Have That No Competitor Can Replicate

• The Existing Patient Relationship: The affected women are already in the waiting room. OB-GYNs see every perimenopausal woman in their 40s for annual well-woman visits. No digital health company, consumer brand, or retail pharmacy has that relationship. The cost of patient acquisition that Midi Health and Hims/Hers are spending tens of millions of dollars on OB-GYNs already have for free.
• Clinical Authority and Full Scope of Care: Only board-certified OB-GYNs can provide the complete clinical spectrum: complex HRT management, non-hormonal Rx, surgical evaluation of co-morbidities, osteoporosis co-management, and cardiovascular risk counselling. NP-led telehealth platforms have real clinical limitations. Physician-led OB-GYN practices do not.
• Insurance Credibility: The OB-GYN visit is covered and trusted by patients and employers in ways that cash-pay DTC platforms are not. As employer benefit plans begin requiring network provider access for menopause care reimbursement, MSCP-certified OB-GYNs will be the essential supply side of that network.

Six Actions for OB-GYN Practices Ready to Lead

1. MSCP Certification: At minimum one, ideally all providers, should pursue MSCP certification. The exam is offered twice annually; the $400 member fee is among the best ROIs in medicine. MSCP practices report more referrals, stronger differentiation, and higher patient satisfaction within 12 months of certification.
2. Dedicated Appointment Architecture: Create specific appointment types for menopause — a 45-60 minute new patient menopause intake and 20-30 minute follow-ups. These are not well-woman visits. The billing is different; the clinical model is different; the patient experience must be different.
3. Ancillary Revenue Integration: Menopause is a high-ancillary-revenue service line: HRT prescribing, monitoring labs, bone density (DXA), pharmacogenomics, supplements, and compounding pharmacy relationships all generate per-encounter revenue that far exceeds the E/M alone. This is where the EBITDA premium lies.
4. Telehealth Layer: Menopause patients demonstrate strong preference for virtual access for follow-up. Adding telehealth for HRT monitoring, symptom checks, and Rx renewals dramatically increases capacity without proportional overhead. This is the model that makes the PE platforms’ EBITDA margins possible.
5. Employer + Benefit Platform Outreach: Contact Maven, Progyny, and Carrot Fertility about network inclusion. Employers are actively seeking MSCP-certified menopause providers. These platforms need credentialed OB-GYNs in their networks — but they need to be approached.
6. Become the Community Voice: Women are searching for trustworthy menopause information in a market flooded with consumer noise. OB-GYN practices that invest in patient education — newsletters, webinars, social media content from MSCP-certified physicians — build public trust and clinical authority that telehealth startups are spending millions to acquire. The OB-GYN has it by default. Use it.

FINAL PERSPECTIVE: The $40 billion menopause market did not exist because of digital health entrepreneurs or consumer brands. It exists because 55 million American women have a clinical need and the specialty best equipped to serve it failed to do so for two decades. That can change — but only if OB-GYN practices treat menopause not as an afterthought of women’s reproductive care, but as the primary clinical opportunity of midlife women’s health. The practices that understand this now will own the market. The practices that wait will find it owned by others.

Appendix: Significant Menopause & Perimenopause Transactions (2023–2026)

The following table summarizes significant venture funding rounds, strategic acquisitions, and fund launches focused on menopause and perimenopause care from 2023 through early 2026. Menopause-focused startups raised over $200 million between 2022 and 2025 alone, and the broader femtech sector deployed approximately $530 million into menopause care from 2015 through Q1 2023, per PitchBook and Crunchbase data cited by SJF Ventures. The pace of investment has accelerated sharply: Midi Health’s $100 million Series D in February 2026 — valuing the company at over $1 billion — marked the first menopause-focused unicorn and signaled that institutional capital now views midlife women’s health as a core growth vertical, not a niche category.

Sources: PitchBook company profiles; SJF Ventures / PitchBook landscape analysis (2023); Fierce Healthcare; TechCrunch; Business Wire; Fortune; New Market Pitch Femtech Funding Trends (2026). Deal values as publicly disclosed; some round sizes are approximate.

Key trend: Capital concentration is notable. Midi Health alone has raised over $250 million to date, accounting for nearly half of all dedicated menopause-care venture funding since 2015. Meanwhile, strategic acquirers are entering the space. Pharmavite’s $425 million acquisition of Bonafide Health in 2023 remains the largest menopause-focused M&A transaction on record. The emergence of dedicated fund vehicles (Portfolia FemTech Fund IV) and the entry of growth-stage investors (Goodwater, Foresite, Index Ventures) into menopause deals suggest the sector is transitioning from early-stage experimentation to institutional-scale deployment.